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Abstract
Alopecia areata (AA) is a common and complex T-cell–mediated inflammatory disorder. 
It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alo-
pecia universalis). Alopecia totalis and universalis are often difficult to treat. Although 
many therapeutic options currently exist in alopecia areata, none of them are curative 
or preventive. Besides, none of them are approved by Food and Drug Administration 
(FDA). The disease unfortunately has an unpredictable course. The factors indicating a 
poor prognosis are the extent of hair loss at the presentation, long duration of the disease, 
and ophiasis pattern of hair loss. There are only a few randomized controlled studies 
conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent 
developments in immunopathogenesis, together with the shared pathways of the disease 
with other autoimmune disorders, led investigators to focus on novel therapies that tar-
get specific immunological pathways. Herein, we will review shortly the current treat-
ment options in recalcitrant alopecia areata based on recently published studies and then 
will focus on the recently developed broad-spectrum and targeted therapeutics.
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1. Introduction
Alopecia areata (AA) is a common immune-mediated disorder [1]. It affects 0.1–0.2% of the 
general population and accounts for 0.7% to 3.8% of all patients attending to dermatology 
clinics [1, 2]. It affects both genders equally. Although onset may occur at any age, 60% of new 
cases had their first diagnosis before 20 years age [1, 2].
Despite its high prevalence, the exact cause and triggering factors of AA are still 
unknown [1–3]. It is considered to be a complex genetic, immune-mediated disease [1–5]. It 
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targets primarily hair follicles and characterized by dense peribulbar lymphocytic infiltrate 
[4, 6]. Hair follicle is a dynamic immune privileged “miniorgan” with unique immune and 
hormone microenvironments. This means that hair follicles are immune-protected sites With 
deficient major histocompability complex (MHC) expression [7, 8]. Evidence suggests that 
AA results from the loss of immune privilege with presentation of autoantigens, triggered by 
environmental factors in genetically susceptible individuals [1, 3, 7–9]. Many genes that are 
found to be associated with AA are also related to the immune system [3, 9]. Cytotoxic CD8+ 
NKG2D+ T cells are key players in the pathogenesis of AA that produce interferon-γ (IFN-γ) 
[5, 10]. Interleukin (IL)-2 and IL-15 are well known drivers of cytotoxic activity by IFN-γ-
producing CD8+ Tcells and natural killer (NK) cells [10]. Besides, recently published studies 
investigating the cytokine profile in lesional AA scalp indicates concurrent activation of Th1 
and Th2 immune axes, as well as interleukin (IL)-23 and IL-32 cytokine pathways [11–13]. 
Also, in another recent study, it was supported that Th1-type cytokine profile is related to dis-
ease activity of AA, whereas Th2-type cytokines may be associated with the persistence of AA 
[14]. It is significant to understand both the pathomechanism of AA and responsible cytokines 
in order to develop new treatments for recalcitrant AA [3, 6, 7, 13].
In AA, most commonly affected area is the scalp [1, 2]. On scalp, it usually presents with well 
demarcated, one or more hairless patches with preserved follicular ostia and without ery-
thema [1]. If 100% of the scalp hair is lost, it is named as alopecia totalis (AT). Any hair-bearing 
area such as beard, eyebrows, eyelashes, body, armpits, and pubic region may also be affected 
in AA, as well as the entire body, alopecia universalis (AU) [1, 2, 15]. Depending on the extent 
of involvement, AA can be associated with a dramatic reduction of quality of life [1, 2, 16, 17].
The association with other autoimmune diseases such as thyroid diseases, vitiligo, diabetes 
mellitus, pernicious anemia, rheumatoid arthritis may be seen with AA [2, 6, 17–19]. Atopy is 
twice as common in AA patients as it is in the general population [2, 16]. Other diseases and 
genetic disorders reported to be associated with AA include Down syndrome, Addison’s dis-
ease, autosomal recessive autoimmune polyglandular syndrome, psoriasis, lupus, ulcerative 
colitis, and multiple sclerosis. These less common disorders are more likely to be associated 
with AT and AU [2].
AA has an unpredictable outcome [1, 2, 16]. Up to 50% of patients with limited patchy AA will 
recover within 1 year even without treatment [16, 17]; while 7–10% of patients can eventually 
develop the severe chronic form of the condition, which is refractory to most of the treatments 
[20]. The factors indicating a poor prognosis are the extent of hair loss presentation (extensive 
AA/AT/AU), an ophiasis pattern of hair loss, onset in childhood, a long duration of hair loss, 
associated atopy or autoimmune disease [1, 16, 17, 19]. The chance of full recovery is less than 
10% in AT/AU [2].
2. Treatment
2.1. Conventional therapies
For the disease of AA, there exists currently neither a universally proven therapy that induces 
and sustains remission, nor a cure [21]. Various treatments are available; however, only a few 
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randomized controlled studies in AA have been published [22]. Current treatment options 
include a variety of topical, intralesional, and systemic agents with the choice and recom-
mendation based on the disease extent, duration of disease, associated disorders, and age of 
the patient [15, 23–25].
For recalcitrant AA, and particularly the AT and AU forms, finding appropriate therapeu-
tics among currently available options is very challenging [13]. Current systemic treatment 
options mostly show limited efficacy and are often associated with major adverse effects in 
these cases [15, 24].
In this chapter, different treatment modalities in AA will be reviewed. As discussion of all the 
treatment modalities for AA is beyond the scope of this chapter, instead we rather focused 
our attention on current treatment regimens for recalcitrant and extensive AA, and on novel 
treatment modalities, which are still being under investigation.
2.1.1. Corticosteroids
2.1.1.1. Topical corticosteroids
Midpotent and potent topical corticosteroids (CSs) are usually used to treat AA, especially 
patchy type AA, but the evidence for their effectiveness is limited in recalcitrant AA [23–26]. 
CSs are thought to affect peribulbar lymphocytes and decrease inflammation around the bulb 
region, thereby allowing follicles to enter a normal hair cycle [25, 26].
2.1.1.2. Intralesional corticosteroids
For adult patients characterized with limited scalp involvement or in cases with involvement 
of eyebrows, intralesional corticosteroids (ILCSs) are considered as a first-line therapy [15, 21, 
23]. Although, ILCSs have been used for about 50 years, no published randomized controlled 
trials have been found about this treatment in AA [22, 27].
2.1.1.3. Systemic corticosteroids
Systemic CSs are the most useful immunosuppressive therapy for patients with active AA 
[21, 23]. The suggested dosages for AA in adults are 1 mg/kg/day and 0.1–1 mg/kg/day for 
children. The dosages necessary to maintain hair regrowth in AA are daily between 30 mg 
and 150 mg [15]. However, there is little information available on the role of long-term use 
of systemic corticosteroids in chronic refractory AA [16, 24]. Combination with methotrexate 
(MTX) in the treatment of severe long-term AA might be more effective [28].
2.1.1.4. Systemic pulse corticosteroids
Systemic pulse corticosteroid therapy (PCT) is another choice in the treatment of recalci-
trant and extensive AA [17, 23, 29]. The use of PCT was introduced to minimize the side 
effects associated with prolonged systemic corticosteroid therapy. However, placebo-con-
trolled randomized studies with varying dosage schedules are required to standardize the 
treatment regimen, optimize the therapeutic efficacy, and evaluate the long-term outcomes 
[22, 24].
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2.1.2. Topical anthralin (dithranol)
Although the mechanism of anthralin (dithranol) is unknown, the interaction of the drug 
with different cytokines such as IFNs, tumor necrosis factor (TNF), IL-1, and IL-10 points to 
a nonspecific immunomodulatory effect, which is responsible for regrowth [30]. There are a 
small number of uncontrolled case series [22, 30], in which, no randomized controlled study 
was found in recalcitrant AA.
2.1.3. Topical immunotherapy (topical sensitizers)
Topical immunotherapy (TI) with diphenylcyclopropenone (DPCP) or squaric acid dibutyl-
ester (SADBE) is recommended as a first-line therapy in adult patients with AA having more 
than 50% scalp involvement [23, 30]. No randomized controlled trials have been found to 
evaluate the effectiveness of TI in recalcitrant AA [22, 31]. A review of all articles published 
on TI concluded that 50–60% of the patients experienced worthwhile regrowth, although the 
range of response was very broad (9–87%) [31–34].
2.1.4. Topical minoxidil
Minoxidil is a topical preparation, of which the mechanism of action is not fully understood. 
Vasodilatation, angiogenesis, enhanced cell proliferation at the base of the bulb and differen-
tiation above the dermal papilla, and potassium channel opening have all been proposed [23]. 
It was confirmed that topical minoxidil may induce new hair growth in AA but less likely to 
do so in more severe and extensive diseases [23, 24, 35].
2.1.5. Topical prostaglandin analogues
Prostaglandin (PG) F2α and its analogues have been shown to have stimulatory effects on 
murine hair follicles and follicular melanocytes in both telogen and anagen phases and also 
on the stimulation of conversion from telogen to anagen phase [24].
Although reports about effective clinical response have been found [36], two randomized 
controlled studies demonstrated an efficacy of topical latanoprost in the AA [37–39].
2.1.6. Topical bexarotene
Bexarotene is a retinoid X receptor agonist that induces T-cell apoptosis and effects as an immu-
nomodulator [23]. In a randomized half-head trial study including patients of recalcitrant AA 
treated with topical bexarotene, no difference was demonstrated between the two sides [40].
2.1.7. Calcineurin inhibitors
2.1.7.1. Cyclosporine
Cyclosporine (Cyc) is an immunosuppressive agent that inhibits helper T-cell activity and 
suppresses the IFN-γ production. The treatment with Cyc alone or in combination with sys-
temic steroids demonstrated variable clinical results with a response rate between 25% and 
88.4% [17, 41–43].
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Despite these effective results, side effects of Cyc make this therapy not appropriate for the 
long-term use [21]. Neither pimecrolimus nor tacrolimus was shown to be effective in AA 
[44–46].
2.1.8. Methotrexate
Methotrexate (MTX) is an immunosuppressive agent and a folic acid antagonist, which exerts 
its effect by inhibiting DNA synthesis and has anti-inflammatory properties [23].
Although no randomized controlled study has been found, MTX and low doses of oral cor-
ticosteroids might be an effective treatment for resistant AA, which should be evaluated in 
larger series [28, 47, 48].
2.1.9. Azathioprine
Azathioprine (AZT) is a cytotoxic and immunosuppressive drug and has selective effects on T 
lymphocytes [17, 23]. An open-label uncontrolled study and a recently published prospective 
study suggested that AZT Might be an alternative [49, 50].
2.1.10. Sulfasalazine
Sulfasalazine is an immunomodulatory and anti-inflammatory drug that inhibits the release 
of IL-2 and PGE2 and reduces the inflammatory cell chemotaxis and antibody production [51]. 
Several uncontrolled studies have interrogated the efficiency of the drug [51–53]. Although 
there are conflicting results and there is no randomized controlled study, sulfasalazine may 
be a hope for resistant and extensive cases. Additional larger studies should be conducted on 
this subject.
2.1.11. Simvastatin/ezetimibe
Statins are lipid-lowering drugs that also inhibit T-lymphocyte activation, downregulate 
expression of adhesion molecules, and have immunomodulatory effects [54]. Case series were 
reported demonstrating the efficiency of daily dosage of simvastatin 40 mg and ezetimibe 
10 mg in AA [55–57]. Contrarily, Loi et al. reported a study of 20 patients (17 patients were 
evaluated) with recalcitrant AA, in which 14 of 17 were unresponsive [58]. All of these reports 
suggest that simvastatin/ezetimibe might be a promising agent in AA. Further randomized 
controlled studies are needed in recalcitrant AA.
2.1.12. Phototherapy
Having effects on Langerhans cells, cytokine profile, inducing apoptosis and promotion of 
immunosuppression make phototherapy a choice of treatment in AA [59]. There are several 
uncontrolled studies of psoralen plus ultraviolet A (PUVA) light with either oral or topical 
psoralens and either with local or whole body irradiation with response rates up to 60% in 
AA [60–62]. However, two retrospective reviews reported that PUVA is not an effective treat-
ment method in AA [63, 64]. No randomized controlled trials for neither PUVA nor narrow 
band ultraviolet B (nbUVB) treatments have been found. A recent study suggested that the 
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combination therapy with topical Cyc and PUVA may be an additional choice for severe and 
recalcitrant AA [65]. Four patients were reported responding by both clinically and histo-
pathologically to UVA1 therapy [66].
2.1.13. Laser therapy
Recently, there has been a great interest in the potential treating role of laser and light-based 
therapies in various disorders including AA [67–69]. A study which investigated the efficacy 
of pulsed diode laser (904 nm) in the treatment of resistant patchy AA reported a regrowth 
rate in 94% of the patients, while no response was shown in control patches [68].
The efficacy of excimer laser was investigated in various reports with a failure of regrowth 
[69–72].
2.1.14. Miscellaneous treatments
Inosiplex (Isoprinosine): Inosiplex, an immunomodulator, was tried in a randomized controlled 
study with recalcitrant AA and significant regrowth was observed in the group treated with 
inosiplex [73].
Platelet-rich plasma (PRP): There are reports showing the efficacy of PRP in extensive AA [74–
76]. A case with ophiasis type AA was reported to be treated successfully with PRP [74]. 
A recently published randomized controlled study suggested that PRP might be a safe and 
effective treatment for AA [75].
2.2. Targeted therapies
In recent years, various biological agents that target pathogenesis have been introduced for 
the treatment of various diseases. Understanding the pathomechanism of AA has led inves-
tigators to do research about the efficacy of new biological treatments in AA. There are still 
multiple possible therapeutic targets being explored. After going through the above men-
tioned current treatments, the below section will focus on the recent broad-spectrum and 
targeted therapeutics, centering upon suggested AA immune pathways.
2.2.1. Tumor necrosis factor (TNF)-α inhibitors
TNF-α is a proinflammatory cytokine that mediates inflammation and has a role in cell prolif-
eration and differentiation [77]. TNF-α was shown to be elevated in the serum of patients with 
AA [78] and in lesional AA skin than nonlesional skin [12]. Although this evidence suggests 
that blocking TNF activity may improve AA, a clinical trial of 17 individuals was performed 
to investigate the effect of etanercept in AA. As a result of the study, it was found as ineffec-
tive [79]. Several reports have been published indicating the development of AA during a 
treatment of anti-TNF-α for another disease [80–86]. Gorcey et al. reported a patient with AU, 
refractory to various treatment modalities, who was successfully treated with adalimumab, 
while being treated for the flare of atopic dermatitis [87].
Pharmacogenetics and the inherent physiologic levels of TNF may explain why TNF inhibi-
tors cause AA in some individuals, while treating AA in others. These conclusions warrant 
further investigation on this subject.
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2.2.2. IL-23 pathway antagonism
2.2.2.1. Ustekinumab
Ustekinumab is a human monoclonal IgG1 antibody that binds with the p40 subunit of IL-12 
and IL-23 and inhibits their activity [88].
The Th17 immunologic pathway and associated cytokines including IL23 and IL17 are important 
in the pathophysiology of psoriasis, psoriatic arthritis, and other spondyloarthropathies [13, 89].
Many studies have demonstrated that IL-23 has an important role by driving the expansion 
and functional maintenance of Th17 development [90].
Suárez-Fariñas et al. performed a study on microarray and RT-PCR profile of 27 lesional and 
17 nonlesional scalp samples from patients with AA and compared them with normal scalp 
samples (n=6). Genes associated with T-cell migration/activation were found to be signifi-
cantly induced in lesional vs. nonlesional AA tissues. IL-12/23p40 showed the highest increase 
in mRNA expression of all measured inflammatory markers in lesional scalp of AA compared 
with normal scalp from healthy subjects [12]. As increased Th1 serum cytokine levels have 
been associated with extensive AA, IL-12 inhibitors (ustekinumab) would be expected to treat 
or at least to prevent hair loss [11, 91].
Guttman-Yassky et al. demonstrated hair regrowth in three extensive AA patients (one had 
AU) treated with 90 mg subcutaneously. At the 20th week, all patients exhibited varying 
degrees of hair regrowth. The patient with AU, with the highest baseline inflammation and 
lowest expression of hair keratins, exhibited the highest regrowth [92].
On the other hand, case reports of AA developing during treatment with ustekinumab for 
psoriasis have also been published [93–95].
Future clinical trials including larger samples are needed to clarify the clinical efficacy of 
usteukinumab in AA.
2.2.3. Th17/IL-17 antagonism
2.2.3.1. Secukinumab
Secukinumab is a recombinant, high-affinity, fully human IgG1κ monoclonal antibody that 
selectively inhibits IL-17A [12, 96, 97].
IL-17A is known to induce the expression of T-cell and dendritic cell chemokines, which lead 
to the migration of memory T cells and dendritic cells to the inflammation area [97].
Tanemura et al. found the infiltration of CD4(+)IL-17A(+) Th17 cells in the dermis, particularly 
around hair follicles, in all 4 cases in their study [98].
A recent study by Atwa et al. examined IL-17, IL-21, IL-22, IL-6, and TNF-α levels in the 
serum of patients with AA and studied their association with the clinical type and severity of 
AA. All of these cytokines were found to be significantly higher in the AA group than in the 
control group. Significant positive correlations between the serum IL-17 and disease severity, 
between the serum TNF-α and disease severity were detected. Also significant positive cor-
relation between serum IL-22 and duration of AA was detected [99].
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Lew et al. conducted a case-control association study of 238 AA patients, in which, IL17A and 
IL17RA (IL-17A receptor) gene polymorphisms were detected [100].
These studies support a possible role for an anti-IL-17 treatment in AA. Secukinumab is being 
tested in a double-blind, randomized, placebo-controlled clinical trial for AA (ClinicalTrials.
gov NTC02599129).
2.2.4. Broad T-cell inhibition
2.2.4.1. Apremilast
Apremilast is an orally available molecule that inhibits phosphodiesterase 4 (PDE4) [13, 101]. 
It is approved in the treatment of psoriasis, psoriatic arthritis, and currently tested in trials for 
atopic dermatitis, and other inflammatory and dermatological conditions [102].
Inhibition of PDE4 leads to reduced production of proinflammatory mediators, such as TNF, 
IFN-γ, IL-12/23p40, IL-17A, and IL-22 [101, 102]. On the other hand, apremilast has been 
reported to increase the production of IL-6 and IL-10 [101–104]. This is of interest, since IL-10 
is a cytokine with potent anti-inflammatory properties, while IL-6 is a cytokine with pro-
and anti-inflammatory features [101]. Apremilast also exerts its effects by hydrolyzing cyclic 
adenosine monophosphate (cAMP) and thus affects various inflammatory mediators. PDE4 
antagonism results in elevated intracellular cAMP [101–103].
In a study by Keren et al. PDE4 was found highly elevated in the lesions of AA in a mouse 
model of AA; apremilast was shown to be effective with almost complete preservation of hair 
follicules and resulted significant in reductions in inflammatory cytokines, such as PDEe, 
IFN-γ, and TNF-α [105]. Suárez-Fariñas et al. reported a highly increase of PDE4 in human 
AA lesions in their study [12]. In a furher study by Guttman-Yassky et al., levels of PDE4 were 
found to decrease after treatment with IL-12/IL-23 antagonist [92].
Apremilast might be an appropriate therapeutical option for AA and is under being investiga-
tion as a clinical trial (ClinicalTrials.com NCT02684123).
2.2.4.2. Janus kinase inhibitors
Janus kinase (JAK) inhibitors are potent antiinflammatory and antiproliferative agents [13, 
106]. Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of 
rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of 
polycythemia vera and myelofibrosis [107].
JAK family of protein-tyrosine kinases is made of four members: JAK1, JAK2, JAK3 and TYR2 
(Tyrosine kinase2). The JAK/STAT pathway transduces extracellular signals from a variety of 
cytokines, growth factors and hormones to the nucleus and is responsible for the expression 
of thousands of protein-encoding genes [107, 108]. Targeting JAK1 or JAK2 was thought to be 
helpful for interfering with the signaling pathways implicated in the generation of pathogenic 
Th1 and Th17 cells in autoimmunity [106].
The possibility of reversal of AA by JAK inhibitors was successfully shown in murine 
model by blocking IFN-γ and interleukin-2 (IL-2) or IL-15 receptor β and by reducing the 
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 accumulation of CD8 + T cells [10, 109, 110]. Both JAK1 and JAK2 (ruxolitinib, baricitinib) 
and JAK3 (tofacitinib) inhibitors have been reported to effectively treat AA in various case 
reports [109–112].
Craiglow and King reported a patient with psoriasis who also had long standing AU. After 
8 months of treatment with tofacitinib, the patient had full regrowth of hair on scalp along 
with significant regrowth on eyelashes, eyebrows and other body sides [111].
Jabbari et al. studied the effect of tofacitinib by clinically and by the changes in expression of 
AA- associated genes in skin as well as circulating CXCL10 levels with result sof significant 
hair growth along with change in skin and biochemical markers [109].
Gupta et al. reported two cases of recalcitrant AU treated with tofacitinib. Both cases showed 
full regrowth of hair on the body at the end of 8 months of treatment [112].
A case with AU treated with tofacitinib with a transient efficacy has also been reported [113].
Today, there are ongoing clinical trials for tofacitinib (ClinicalTrials.gov NCT02312882, 
NCT02197455, NCT02299297 and NCT02812342), ruxolitinib (NCT01950780), and baricitinib 
in the treatment of AA and in various inflammatory diseases, which will make us understand 
the exact effect of these treatments [13].
Topical JAK inhibitors have also been shown as effective in AD, psoriasis, dry eye disease and 
in allergic contact dermatitis model [114–117]. Topical JAK inhibitors may offer a good treat-
ment option for especially for limited AA [13].
JAK inhibitors may replace some immunosuppressive treatments. Further clinical trials are 
warranted to clarify the exact effects of JAK inhibitors in AA.
2.2.4.3. Abatacept
Abatacept is a fusion protein of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with 
a portion of IgG1 (CTLA-4Ig) that selectively modulates T-cell co-stimulation. It binds to 
CD80/CD86 receptors on antigen-presenting cells and by this way blocks the interaction of 
CD80/86 with CD28 which is found on T-cells and inhibits full T-cell activation [118, 119]. 
In vitro, abatacept decreases T-cell proliferation, the production of inflammatory cytokines 
such as IFN-γ, TNF-α and IL-2 and B-cell immunological response [118]. Also, it was found 
to increase Treg cells, which was linked to downregulation of activation-associated marker 
molecules [120]. Abatacept is currently being used in rheumatoid arthritis with FDA approve-
ment [13]. Since T-cell activation is crucial in the development of AA [9], there is a poten-
tial chance for abatacept in the treatment of AA. There is an ongoing study for abatacept 
(ClinicalTrials.gov NCT02018042).
2.2.5. IL-2 modulation as a modifier of regulatory function
2.2.5.1. Aldesleukin
Aldesleukin is a recombinant interleukin-2 (IL-2) molecule and a biological response modifier 
having various immunomodulatory properties [121]. Aldesleukin is currently approved only 
for treatment of renal cell carcinoma and metastatic melanoma and is usually used in high 
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doses in these indications [122, 123]. It can be applied via intravenous or subcutaneous admin-
istration. In high intravenous bolus regimen, it has been reported to be highly toxic [121]. IL-2 
is a key cytokine for T regulatory (reg) cell differentiation, homeostasis and functions [124]. In 
AA, an imbalance in the immune state of patients has been detected with altered T-helper cell 
and Treg cell functions [125, 126]. A study by Shin et al. revealed impaired function of CD4 T 
reg cells [127]. A study by Castela et al. evaluated the efficacy of low dose recombinant IL-2 
treatment on five AA patients. Four of five patients had partial regrowth and the improve-
ment continued up to 6 months after drug cessation. Pre and posttreatment biopsies were 
taken to compare the level of T reg cells and an increase was detected in posttreatment group 
[128]. Aldesleukin is now being under investigation and clinical studies with larger samples 
are needed to assess the exact efficacy of the drug (ClinicalTrials.gov NCT01840046).
2.2.6. Th2 pathway inhibition
2.2.6.1. Dupilumab
Dupilumab is a fully human monoclonal antibody directed against the α subunit of IL-4 
receptor. It blocks the signaling of IL-4 and IL-13, both of which are the key cytokines in Th2-
mediated pathways [13, 129]. The efficacy of dupilumab has been studied in atopic dermatitis 
(AD) and asthma with a rapid, significant clinical improvement [129–133]. Also, decreasing 
in the levels of serum and skin Th2 markers and Th17/IL-23 associated markers have been 
demonstrated [129].
Several studies support a shared genetic background between AA and AD, besides both dis-
eases were shown to have upregulation of Th2 component and an IL-23 [12, 134, 135]. The 
history of atopy and autoimmune disease was also found to be associated with an increased 
risk of AA [2, 16, 136].
Suarez-Farinas et al. reported a study of 22 patients who also had AD. They sought a detailed 
molecular profile of the lesional and nonlesional AA transcriptomes with AA. A significant 
upregulation of Th2 cytokine IL-13 was found similar to AD lesions. A possible pathogenic 
role of Th2 axis in patients with AA was supported as a result of this study [12].
Fuentes-Duculan et al. studied pre- and posttreatment lesional biopsies of 6 patients with 
patchy AA and performed immunohistochemistry and gene expression analysis. They found 
a significant expression of inflammatory markers of IL-2, IL-15, Th1 and Th2 (IL-13, CCL17 
and CCL18), IL-12/IL-23p40 before treatment. After treatment with intralesional corticoste-
roid injection, a significant downregulation was observed in IL-12/IL-23p40, CCL18 [11].
Sharing possible common pathways both in AA and AD make dupilumab also worth triable 
in AA.
2.2.6.2. Tralokinumab
Tralokinumab is an IgG4 humanized monoclonal antibody that targets neutralising IL-13 
[13, 137]. IL-13 is a Th2 cell cytokine and has an important role in atopy [137]. Tralokinumab 
is under investigation for asthma and AD (ClinicalTrials.gov NC). As mentioned above, 
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 Suárez-Fariñas et al. found the highest levels of IL-13 and IL23p40 mRNA expressions in 
lesional vs. nonlesional AA and in lesional AA vs. healthy subjects [12]. Tembhre et al. 
found significant high levels of IL-13 and IL-17A which suggested altered Th cell function 
[125].
These findings support a possible role of tralokinumab in AA which is now being under 
investigation (ClinicalTrais.gov NCT02684097).
3. Conclusions
Currently, many therapies are available and the treatment depends on many factors, such as 
the severity, extent, duration of the disease, and age of the patient.
Although many treatments are shown to be effective in extensive recalcitrant AA, the most 
important problems of the present studies include the limited number of randomized con-
trolled studies, lack of evaluating the long-term efficacy and follow-up, small number of par-
ticipants, and significant disease heterogeneity in patient selection.
Better understandings of the immunopathological mechanisms responsible in AA have led 
the clinical researches to develop better therapeutic options for AA. However, future larger 
studies are needed to clarify the immunological pathways responsible in AA, which will lead 
to further therapeutic developments.
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